June 15, 2017 / 11:36 PM / a month ago

BRIEF-Paradigm Biopharma says mid-stage hay fever study did not meet main goals

1 Min Read

June 16 (Reuters) - Paradigm Biopharmaceuticals Ltd :

* Phase 2A allergic rhinitis clinical trial did not meet its primary endpoints using current nasal formulation

* Was verbally informed by its contract research organisation of top-line outcomes and anticipates receiving final report shortly Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below